Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation

The aim of the work: to evaluate the prognostic effect of pharmacotherapy before and after radiofrequency ablation (RFA) in patients with atrial fibrillation (AF) on all-cause mortality, supraventricular arrhythmia recurrence and non-fatal cardiovascular events. Materials and methods. Patients wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. S. Brynza, O. V. Bilchenko, O. S. Makharynska, M. I. Shevchuk
Formato:	article
Lenguaje:	EN RU UK
Publicado:	Zaporozhye State Medical University 2021
Materias:	radiofrequency ablation atrial fibrillation prognostic effect Medicine R
Acceso en línea:	https://doaj.org/article/2abffa698f654341b147c7fffe1d1502
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2abffa698f654341b147c7fffe1d1502
record_format	dspace
spelling	oai:doaj.org-article:2abffa698f654341b147c7fffe1d15022021-11-05T07:56:51ZPrognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation10.14739/2310-1210.2021.6.2299732306-41452310-1210https://doaj.org/article/2abffa698f654341b147c7fffe1d15022021-11-01T00:00:00Zhttp://zmj.zsmu.edu.ua/article/view/229973/241655https://doaj.org/toc/2306-4145https://doaj.org/toc/2310-1210The aim of the work: to evaluate the prognostic effect of pharmacotherapy before and after radiofrequency ablation (RFA) in patients with atrial fibrillation (AF) on all-cause mortality, supraventricular arrhythmia recurrence and non-fatal cardiovascular events. Materials and methods. Patients with paroxysmal, persistent and long-term persistent forms of AF were examined before and after RFA – isolation of pulmonary veins. The primary endpoint was patient survival, secondary – a composite endpoint of freedom from recurrence and/or non-fatal cardiovascular events for 2 years of a follow-up. Frequency and doses of pharmacotherapy were evaluated. Standard statistical procedures were used for initial data evaluation. Results. 116 patients were consecutively enrolled in the study. In the long-term post-ablation, 23 patients (19.8 %) continued to take amiodarone, 2 patients (1.7 %) – propafenone for arrhythmic events, 38 patients (32.8 %) needed anticoagulants, and 37 patients (31.9 %) received beta-adrenoceptor blockers over the entire follow-up period. The use of RAAS inhibitors decreased from 81.0 % before the ablation to 56.0 % in the long-term period following RFA. Multifactorial logistic regression analysis showed that the prolonged (more than 3 months) anticoagulation (P = 0.032) after RFA was an independent predictor of patient survival in the two-year follow-up; doses of anticoagulants before the procedure, use and doses of beta-adrenoceptor blockers in the long-term post-ablation period were associated with the secondary endpoint. Conclusions. RFA for AF significantly reduced the frequency of medications use in the long-term postoperatively. Independent predictors of survival were the doses of anticoagulants more than 3 months after ablation, arrhythmia recurrence and non-fatal cardiovascular events – the doses of anticoagulants before the procedure, and the use and doses of beta-adrenoceptor blockers in the long-term period after RFA. M. S. BrynzaO. V. BilchenkoO. S. MakharynskaM. I. ShevchukZaporozhye State Medical Universityarticleradiofrequency ablationatrial fibrillationprognostic effectMedicineRENRUUKZaporožskij Medicinskij Žurnal, Vol 23, Iss 6, Pp 772-777 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU UK
topic	radiofrequency ablation atrial fibrillation prognostic effect Medicine R
spellingShingle	radiofrequency ablation atrial fibrillation prognostic effect Medicine R M. S. Brynza O. V. Bilchenko O. S. Makharynska M. I. Shevchuk Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
description	The aim of the work: to evaluate the prognostic effect of pharmacotherapy before and after radiofrequency ablation (RFA) in patients with atrial fibrillation (AF) on all-cause mortality, supraventricular arrhythmia recurrence and non-fatal cardiovascular events. Materials and methods. Patients with paroxysmal, persistent and long-term persistent forms of AF were examined before and after RFA – isolation of pulmonary veins. The primary endpoint was patient survival, secondary – a composite endpoint of freedom from recurrence and/or non-fatal cardiovascular events for 2 years of a follow-up. Frequency and doses of pharmacotherapy were evaluated. Standard statistical procedures were used for initial data evaluation. Results. 116 patients were consecutively enrolled in the study. In the long-term post-ablation, 23 patients (19.8 %) continued to take amiodarone, 2 patients (1.7 %) – propafenone for arrhythmic events, 38 patients (32.8 %) needed anticoagulants, and 37 patients (31.9 %) received beta-adrenoceptor blockers over the entire follow-up period. The use of RAAS inhibitors decreased from 81.0 % before the ablation to 56.0 % in the long-term period following RFA. Multifactorial logistic regression analysis showed that the prolonged (more than 3 months) anticoagulation (P = 0.032) after RFA was an independent predictor of patient survival in the two-year follow-up; doses of anticoagulants before the procedure, use and doses of beta-adrenoceptor blockers in the long-term post-ablation period were associated with the secondary endpoint. Conclusions. RFA for AF significantly reduced the frequency of medications use in the long-term postoperatively. Independent predictors of survival were the doses of anticoagulants more than 3 months after ablation, arrhythmia recurrence and non-fatal cardiovascular events – the doses of anticoagulants before the procedure, and the use and doses of beta-adrenoceptor blockers in the long-term period after RFA.
format	article
author	M. S. Brynza O. V. Bilchenko O. S. Makharynska M. I. Shevchuk
author_facet	M. S. Brynza O. V. Bilchenko O. S. Makharynska M. I. Shevchuk
author_sort	M. S. Brynza
title	Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
title_short	Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
title_full	Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
title_fullStr	Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
title_full_unstemmed	Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
title_sort	prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation
publisher	Zaporozhye State Medical University
publishDate	2021
url	https://doaj.org/article/2abffa698f654341b147c7fffe1d1502
work_keys_str_mv	AT msbrynza prognosticvalueofpharmacotherapyinpatientswithatrialfibrillationafterradiofrequencyablation AT ovbilchenko prognosticvalueofpharmacotherapyinpatientswithatrialfibrillationafterradiofrequencyablation AT osmakharynska prognosticvalueofpharmacotherapyinpatientswithatrialfibrillationafterradiofrequencyablation AT mishevchuk prognosticvalueofpharmacotherapyinpatientswithatrialfibrillationafterradiofrequencyablation
_version_	1718444457621192704

Prognostic value of pharmacotherapy in patients with atrial fibrillation after radiofrequency ablation

Ejemplares similares